Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Price Monitoring Extension

November 9, 2022
RNS Number : 8850F Renalytix PLC 09 November 2022   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

Renalytix to Present at Stifel Healthcare Conference

November 3, 2022
NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel.

RENX to Present at Stifel Healthcare Conference

November 3, 2022
RNS Number : 1206F Renalytix PLC 03 November 2022     Renalytix plc ("Renalytix" or the "Company")   Renalytix   to Present at Stifel Healthcare Conference   NEW YORK, NY and SALT LAKE CITY, UT    ̶  November 3, 2022   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will

Second Price Monitoring Extn

October 31, 2022
RNS Number : 7950E Renalytix PLC 31 October 2022   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this

Price Monitoring Extension

October 31, 2022
RNS Number : 7941E Renalytix PLC 31 October 2022   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

Renalytix Reports Full Year Fiscal 2022 Results

October 31, 2022
LONDON and SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based

Renalytix Reports Full Year Fiscal 2022 Results

October 31, 2022
RNS Number : 5791E Renalytix PLC 31 October 2022   Renalytix plc (" Renalytix ", the "Group" or the " Company ")   Renalytix Reports Full Year Fiscal 2022 Results   LONDON and SALT LAKE CITY , October 31, 2022   -  Renalytix plc   (NASDAQ: RNLX),  (LSE : RENX)   an artificial intelligence-enabled

Second Price Monitoring Extn

October 26, 2022
RNS Number : 1692E Renalytix PLC 26 October 2022   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this

Price Monitoring Extension

October 26, 2022
RNS Number : 1684E Renalytix PLC 26 October 2022   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders

KidneyIntelX Medicare Update

October 25, 2022
RNS Number : 9479D Renalytix PLC 25 October 2022     Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX   Medicare Update   NEW YORK and SALT LAKE CITY , October 25, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that, building on recently established private payer and
Displaying 191 - 200 of 513